1. Munzel T, Sinning C, Post F et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40 (3): 180–96, 653–8.
2. Pahkala K, Heinonen OJ, Lagstrom H et al. Vascular endothelial function and leisure-time physical activity in adolescents. Circulation 2008; 118 (23): 2353–9.
3. Brunner HR. (2002) The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 16 (Suppl. 2): S13–16.
4. Puchler K, Laies P, Stumpe K. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001; 19: S41–S48.
5. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
6. Norwood D, Branch E, Smith B et al. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast 2002; 27: 611–8.
7. Chrysant SG, Marbury TC, Robinson TD. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425–32.
8. Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit 2006; 11: 135–41.
9. Рекомендации РМОАГ/ВНОК по диагностике и лечению артериальной гипертонии (4-й пересмотр), 2010.
10. Barrios V, Boccanelli A, Ewald S et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007; 27: 545–58.
11. Chrysant SG, Melino M et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.
12. Kereiakes DJ, Neutel JM, Punzi HA et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 2007; 7: 361–72.
13. Neutel JM, Smith DH, Silfani TN et al. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006; 20: 255–62.
14. Neutel JM, Smith DH, Weber MA et al. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004; 6: 168–74.
15. Naya M, Tsukamoto T, Morita K et al.  Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007; 50 (12): 1144–9.
16. Smith RD, Yokoyama H, Averill DB et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006; 6 (5): 335–42.
17. Stumpe K, Agabiti-Rosei E, Zielinski T et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II receptor blockade. The multicentre olmesartan atherosclerosis regression evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007; 1 (2): 97–106.
18. Hirohata A, Yamamoto K, Miyoshi T et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010; 55 (10): 976–82.
19. Ikeda H, Hamamoto Y, Honjo S et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009; 83 (1): 117–8.
20. Haller H, Ito S, Izzo JL et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.
21. Чазова И.Е., Фомин В.В. Управление кардиоренальным синдромом: возможности блокаторов рецепторов ангиотензина II. Фарматека. 2011; 15: 10–4.
22. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinfl ammation. Circulation 2004; 110 (9): 1103–7.
23. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004; 26 (Suppl. A): A28–A32.
24. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
25. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexitil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23: 419–30.
26. Zanorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56: 1131–4.
27. De Luis DA, Conde R, Gonzalez Sagrado M. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. Eur Rev Med Pharmacol Sci 2010; 14: 759–63.
28. Fabia MJ, Abdilla N, Oltra R et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25 (7): 1327–36.

Г.А.Барышникова, С.А.Чорбинская, И.И.Степанова, Н.В.Чупрова

Кафедра семейной медицины ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва